Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico

Infection, Genetics and Evolution

Volumn 19, Issue , 2013, Pages 330-334

  Cuevas Córdoba, Betzaida ^a   Xochihua González, Sheila Oyuki ^a   Cuellar, Aremy ^b   Fuentes Domínguez, Javier ^c   Zenteno Cuevas, Roberto ^a  

^a UNIVERSIDAD VERACRUZANA   (Mexico)

^b Laboratorio Estatal de Salud Pública de Los Servicios de Salud de Veracruz   (Mexico)

^c Servicios de Salud de Veracruz   (Mexico)

Author keywords

Drug resistance; PncA mutations; Pyrazinamide; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIUM ISOLATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNCA GENE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

DRUG-RESISTANCE; PNCA MUTATIONS; PYRAZINAMIDE; TUBERCULOSIS;

ADULT; AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; MEXICO; MIDDLE AGED; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRAZINAMIDE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84885190941     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2012.12.013     Document Type: Article

References (32)

1. Bishop K.S., Trollip A.P., Smith A.N., Roux L., York D.F., Kiepiela P. Characterization of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. Int. J. Tuberc. Lung. Dis. 2001, 5:952-957.
2. Hou L., Osei-Hyiaman D., Zhang Z., Wang B., Yang A., Kano K. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from china. Epidemiol. Infect. 2000, 124:227-232.
3. Jonmalung J., Prammananan T., Leechawengwongs M., Chaiprasert A. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol. 2010, 10:223.
4. Juréen P.W.J., Toro J.C., Hoffner S. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2008, 52:1852-1854.
5. Lee K.W., Lee J.M., Kung K. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J. Korean Med. Sci. 2001, 16:537-543.
6. Lemaitre N.S.W., Truffot-Pernot C., Jarlier V. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase pncA. Antimicrob. Agents Chemother. 1999, 43:1761-1763.
7. Mphahlele M., Syre H., Valvatne H., Stavrum R., Mannsåker T., Muthivhi T., Weyer K., Fourie P.B., Grewal H.M.S. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolate. J. Clin. Microbiol. 2008, 46(10):3459-3464.
8. Morlock G.P., Plikaytis B.B., Crawford J.T. Characterization of spontaneous, in vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37rv. Antimicrob. Agents Chemother. 2000, 44:3298-3301.
9. PAHO, 2011. Tuberculosis in the region of the Americas 2009. Regional Report: Epidemiology, Control and Financing. Pan American Health Organization, Washington DC, 2011. Available at: http://new.paho.org/hq/dmdocuments/2010/TB_Reporte_2009.pdf.
10. Petrella S., Gelus-Ziental N., Maudry A., Laurans C., Boudjelloul R., Sougakoff W. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS One 2011, 6:e15785.
11. Portugal I., Barreiro L., Moniz-Pereira J., Brum L. PncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob. Agents Chemother. 2004, 48:2736-2738.
12. Rodrigues V.de F., et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil. Antimicrob. Agents Chemother. 2005, 49:444-446.
13. Sandgren A., Barreiro L., Moniz-Pereira J., Brum L. Tuberculosis drug resistance mutation database. PLoS Med. 2009, 6(2):e1000002.
14. Scorpio A., Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 1996, 2:662-667.
15. Scorpio A., Lindholm-Levy P., Heifets L., Gilman R., Siddiqi S., Cynamon M., Zhang Y. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1997, 41:540-543.
16. Sekiguchi J., Miyoshi-Akiyama T., Augustynowicz-Kopeć E., Zwolska Z., Kirikae F., Toyota E., Kobayashi I., Morita K., Kudo K., Kato S., Kuratsuji T., Mori T., Kirikae T. Detection of multidrug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 2007, 45:179-192.
17. Shi W., Zhang X., Jiang X., Yuan H., Lee J.S., Barry C.E., Wang H., Zhang W., Zhang Y. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011, 333:1630-1632.
18. Somoskovi A., Dormandy J., Parsons L.M., Kaswa M., Goh K.S., Rastogi N., Salfinger M. Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: identification of a species-specific pncA mutation in "Mycobacterium canettii" and the reliable and rapid predictor of pyrazinamide resistance. J. Clin. Microbiol. 2007, 45:595-599.
19. Stoffels K., Mathys V., Fauville-Dufaux M., Wintjens R., Bifani P. Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2012, 56(10):5186-5193.
20. Tracevska T., Jansone I., Baumanis V., Nodieva A., Marga O., Skenders G. Spectrum of pncA mutations in multidrug-resistant Mycobacterium tuberculosis isolates obtained in Latvia. Antimicrob. Agents Chemother. 2004, 48:3209-3210.
21. Van Soolingen D., de Haas P.E., Kremer K. Restriction fragment length polymorphism typing of Mycobacteria. Methods Mol. Med. 2001, 54:165-203.
22. Werngren J., Sturegård E., Juréen P., Ängebyc K., Hoffner S., Schön T. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. Antimicrob. Agents Chemother. 2012, 56:1253-1257.
23. World Health Organization, 2010. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. In: WHO (Ed.), 2010. Available at: < http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf.
24. World Health Organization, 2011. Global Tuberculosis Control: WHO Report 2011. In: WHO (Ed.), 2011. Available in: < http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf.
25. Yu-Chi Ch., Shiang-Fen H., Kwok-Woon Y., Yu-Chin L., Jia-Yih F., Wei-Juin S. Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan. BMC Infect. Dis. 2011, 11:240.
26. Zenteno-Cuevas R., Zenteno J.C., Cuellar A., Cuevas B., Sampieri C.L., Riviera J.E., Parissi A. Mutations in the rpoB and katG genes in resistant clinical isolates of Mycobacterium tuberculosis from Veracruz, Mexico. Mem. Inst. Oswaldo Cruz 2009, 104:468-472.
27. Zenteno-Cuevas R., Rubi A., Fuentes-Dominguez J., Lara-Gonzalez J.L., Escobar-Mesa A. Dynamics of multidrug resistant tuberculosis in Veracruz, Mexico between 2002 and 2008. J. Infect. Developing Countries 2010, 4:776-778.
28. Zenteno-Cuevas R., Cuevas-Cordoba B., Enciso A., Enciso L., Cuellar A. Assessing the utility of three TaqMan probes for the diagnosis of tuberculosis and resistance to rifampin and isoniazid in Veracruz, México. Can. J. Microbiol. 2012, 58:318-325.
29. Zhang H., Bi L.J., Li C.Y., Sun Z.G., Deng J.Y., Zhang X.E. Mutations found in the pncA gene of Mycobacterium tuberculosis in clinical pyrazinamide-resistant isolates from a local region of China. J. Int. Med. Res. 2009, 37:1430-1435.
30. Zhang Y., Permar S., Sun Z.H. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 2002, 51(42):49.
31. Zhang Y., Mitchinson D. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 2003, 7:6-21.
32. Zimic M., Sheen P., Quiliano M., Gutierrez A., Gilman R.H. Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance. Infect. Genet. Evol. 2010, 10:346-349.